FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056532325> ?p ?o ?g. }

• W2056532325 endingPage "291" @default.
• W2056532325 startingPage "284" @default.
• W2056532325 abstract "Purpose To report dosimetry and early toxicity data in breast cancer patients treated with postoperative proton radiation therapy. Methods and Materials From March 2013 to April 2014, 30 patients with nonmetastatic breast cancer and no history of prior radiation were treated with proton therapy at a single proton center. Patient characteristics and dosimetry were obtained through chart review. Patients were seen weekly while on treatment, at 1 month after radiation therapy completion, and at 3- to 6-month intervals thereafter. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0. Frequencies of toxicities were tabulated. Results Median dose delivered was 50.4 Gy (relative biological equivalent [RBE]) in 5 weeks. Target volumes included the breast/chest wall and regional lymph nodes including the internal mammary lymph nodes (in 93%). No patients required a treatment break. Among patients with >3 months of follow-up (n=28), grade 2 dermatitis occurred in 20 patients (71.4%), with 8 (28.6%) experiencing moist desquamation. Grade 2 esophagitis occurred in 8 patients (28.6%). Grade 3 reconstructive complications occurred in 1 patient. The median planning target volume V95 was 96.43% (range, 79.39%-99.60%). The median mean heart dose was 0.88 Gy (RBE) [range, 0.01-3.20 Gy (RBE)] for all patients, and 1.00 Gy (RBE) among patients with left-sided tumors. The median V20 of the ipsilateral lung was 16.50% (range, 6.1%-30.3%). The median contralateral lung V5 was 0.34% (range, 0%-5.30%). The median maximal point dose to the esophagus was 45.65 Gy (RBE) [range, 0-65.4 Gy (RBE)]. The median contralateral breast mean dose was 0.29 Gy (RBE) [range, 0.03-3.50 Gy (RBE)]. Conclusions Postoperative proton therapy is well tolerated, with acceptable rates of skin toxicity. Proton therapy favorably spares normal tissue without compromising target coverage. Further follow-up is necessary to assess for clinical outcomes and cardiopulmonary toxicities. To report dosimetry and early toxicity data in breast cancer patients treated with postoperative proton radiation therapy. From March 2013 to April 2014, 30 patients with nonmetastatic breast cancer and no history of prior radiation were treated with proton therapy at a single proton center. Patient characteristics and dosimetry were obtained through chart review. Patients were seen weekly while on treatment, at 1 month after radiation therapy completion, and at 3- to 6-month intervals thereafter. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0. Frequencies of toxicities were tabulated. Median dose delivered was 50.4 Gy (relative biological equivalent [RBE]) in 5 weeks. Target volumes included the breast/chest wall and regional lymph nodes including the internal mammary lymph nodes (in 93%). No patients required a treatment break. Among patients with >3 months of follow-up (n=28), grade 2 dermatitis occurred in 20 patients (71.4%), with 8 (28.6%) experiencing moist desquamation. Grade 2 esophagitis occurred in 8 patients (28.6%). Grade 3 reconstructive complications occurred in 1 patient. The median planning target volume V95 was 96.43% (range, 79.39%-99.60%). The median mean heart dose was 0.88 Gy (RBE) [range, 0.01-3.20 Gy (RBE)] for all patients, and 1.00 Gy (RBE) among patients with left-sided tumors. The median V20 of the ipsilateral lung was 16.50% (range, 6.1%-30.3%). The median contralateral lung V5 was 0.34% (range, 0%-5.30%). The median maximal point dose to the esophagus was 45.65 Gy (RBE) [range, 0-65.4 Gy (RBE)]. The median contralateral breast mean dose was 0.29 Gy (RBE) [range, 0.03-3.50 Gy (RBE)]. Postoperative proton therapy is well tolerated, with acceptable rates of skin toxicity. Proton therapy favorably spares normal tissue without compromising target coverage. Further follow-up is necessary to assess for clinical outcomes and cardiopulmonary toxicities." @default.
• W2056532325 created "2016-06-24" @default.
• W2056532325 creator A5005973513 @default.
• W2056532325 creator A5009490529 @default.
• W2056532325 creator A5034694632 @default.
• W2056532325 creator A5047461923 @default.
• W2056532325 creator A5056895130 @default.
• W2056532325 creator A5069136703 @default.
• W2056532325 creator A5077778024 @default.
• W2056532325 creator A5083496150 @default.
• W2056532325 creator A5084763037 @default.
• W2056532325 date "2015-06-01" @default.
• W2056532325 modified "2023-10-13" @default.
• W2056532325 title "Early Toxicity in Patients Treated With Postoperative Proton Therapy for Locally Advanced Breast Cancer" @default.
• W2056532325 cites W1965029673 @default.
• W2056532325 cites W1967804683 @default.
• W2056532325 cites W1977166840 @default.
• W2056532325 cites W1983371248 @default.
• W2056532325 cites W1985915407 @default.
• W2056532325 cites W1990963883 @default.
• W2056532325 cites W1993073732 @default.
• W2056532325 cites W1997195945 @default.
• W2056532325 cites W2024526542 @default.
• W2056532325 cites W2041180978 @default.
• W2056532325 cites W2054509904 @default.
• W2056532325 cites W2076514228 @default.
• W2056532325 cites W2082280032 @default.
• W2056532325 cites W2083812135 @default.
• W2056532325 cites W2086862863 @default.
• W2056532325 cites W2100025800 @default.
• W2056532325 cites W2109940830 @default.
• W2056532325 cites W2111008795 @default.
• W2056532325 cites W2118642285 @default.
• W2056532325 cites W2120341554 @default.
• W2056532325 cites W2128922346 @default.
• W2056532325 cites W2140430330 @default.
• W2056532325 cites W2153573877 @default.
• W2056532325 cites W2154375587 @default.
• W2056532325 cites W2154811939 @default.
• W2056532325 cites W2158615473 @default.
• W2056532325 cites W2163910197 @default.
• W2056532325 cites W2166920478 @default.
• W2056532325 cites W2168517539 @default.
• W2056532325 cites W2332829713 @default.
• W2056532325 cites W4361745827 @default.
• W2056532325 doi "https://doi.org/10.1016/j.ijrobp.2015.01.005" @default.
• W2056532325 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4972493" @default.
• W2056532325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25754632" @default.
• W2056532325 hasPublicationYear "2015" @default.
• W2056532325 type Work @default.
• W2056532325 sameAs 2056532325 @default.
• W2056532325 citedByCount "76" @default.
• W2056532325 countsByYear W20565323252015 @default.
• W2056532325 countsByYear W20565323252016 @default.
• W2056532325 countsByYear W20565323252017 @default.
• W2056532325 countsByYear W20565323252018 @default.
• W2056532325 countsByYear W20565323252019 @default.
• W2056532325 countsByYear W20565323252020 @default.
• W2056532325 countsByYear W20565323252021 @default.
• W2056532325 countsByYear W20565323252022 @default.
• W2056532325 countsByYear W20565323252023 @default.
• W2056532325 crossrefType "journal-article" @default.
• W2056532325 hasAuthorship W2056532325A5005973513 @default.
• W2056532325 hasAuthorship W2056532325A5009490529 @default.
• W2056532325 hasAuthorship W2056532325A5034694632 @default.
• W2056532325 hasAuthorship W2056532325A5047461923 @default.
• W2056532325 hasAuthorship W2056532325A5056895130 @default.
• W2056532325 hasAuthorship W2056532325A5069136703 @default.
• W2056532325 hasAuthorship W2056532325A5077778024 @default.
• W2056532325 hasAuthorship W2056532325A5083496150 @default.
• W2056532325 hasAuthorship W2056532325A5084763037 @default.
• W2056532325 hasBestOaLocation W20565323252 @default.
• W2056532325 hasConcept C121608353 @default.
• W2056532325 hasConcept C126322002 @default.
• W2056532325 hasConcept C126838900 @default.
• W2056532325 hasConcept C141071460 @default.
• W2056532325 hasConcept C2777793932 @default.
• W2056532325 hasConcept C2779134260 @default.
• W2056532325 hasConcept C2779244869 @default.
• W2056532325 hasConcept C2779920096 @default.
• W2056532325 hasConcept C2989005 @default.
• W2056532325 hasConcept C43270747 @default.
• W2056532325 hasConcept C509974204 @default.
• W2056532325 hasConcept C530470458 @default.
• W2056532325 hasConcept C71924100 @default.
• W2056532325 hasConceptScore W2056532325C121608353 @default.
• W2056532325 hasConceptScore W2056532325C126322002 @default.
• W2056532325 hasConceptScore W2056532325C126838900 @default.
• W2056532325 hasConceptScore W2056532325C141071460 @default.
• W2056532325 hasConceptScore W2056532325C2777793932 @default.
• W2056532325 hasConceptScore W2056532325C2779134260 @default.
• W2056532325 hasConceptScore W2056532325C2779244869 @default.
• W2056532325 hasConceptScore W2056532325C2779920096 @default.
• W2056532325 hasConceptScore W2056532325C2989005 @default.
• W2056532325 hasConceptScore W2056532325C43270747 @default.
• W2056532325 hasConceptScore W2056532325C509974204 @default.
• W2056532325 hasConceptScore W2056532325C530470458 @default.
• W2056532325 hasConceptScore W2056532325C71924100 @default.

• next